How many drugs treat Burn Wound Infections?

Drug Landscape tracks 8 marketed treatments for Burn Wound Infections (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/burn-wound-infections.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Burn Wound Infections — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Burn Wound Infections (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Burn Wound Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Silvadene	Silver Sulfadiazine	Pfizer	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
Kanacin	KANAMYCIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial	Gap junction beta-2 protein	1973-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Sulfamylon	MAFENIDE	Rising	Methylated Sulfonamide Antibacterial	Carbonic anhydrase 12	1969-01-01
Eryped	Erythromycin ethyl succinate	Arbor Pharms Llc	Macrolide		1965-01-01
Sulfadiazine	SULFADIAZINE	Eli Lilly	Sulfonamide Antibacterial [EPC]	5-hydroxytryptamine receptor 2A	1941-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 2 drugs in Burn Wound Infections
Merck & Co. · 2 drugs in Burn Wound Infections
· 1 drug in Burn Wound Infections
Pfizer · 1 drug in Burn Wound Infections
Rising · 1 drug in Burn Wound Infections
Eli Lilly · 1 drug in Burn Wound Infections
Arbor Pharms Llc · 1 drug in Burn Wound Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Burn Wound Infections:

Cite this brief

Drug Landscape (2026). Burn Wound Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/burn-wound-infections. Accessed 2026-06-10.

Burn Wound Infections full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing